Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Atrial Fibrillation | 97 | 2024 | 5201 | 6.860 |
Why?
|
Thiazoles | 60 | 2024 | 1509 | 6.190 |
Why?
|
Warfarin | 63 | 2024 | 1516 | 6.020 |
Why?
|
Anticoagulants | 78 | 2024 | 4896 | 4.580 |
Why?
|
Pyridines | 62 | 2024 | 2877 | 4.580 |
Why?
|
Embolism | 20 | 2023 | 408 | 3.280 |
Why?
|
Stroke | 63 | 2024 | 9945 | 3.150 |
Why?
|
Hemorrhage | 48 | 2024 | 3604 | 3.010 |
Why?
|
Thromboembolism | 11 | 2021 | 1016 | 1.290 |
Why?
|
Myocardial Infarction | 25 | 2024 | 11891 | 1.250 |
Why?
|
Cardiovascular Diseases | 17 | 2024 | 15740 | 1.060 |
Why?
|
Factor Xa | 5 | 2018 | 168 | 0.970 |
Why?
|
Factor XI | 1 | 2024 | 34 | 0.930 |
Why?
|
Acute Coronary Syndrome | 10 | 2015 | 2362 | 0.890 |
Why?
|
Double-Blind Method | 48 | 2024 | 12412 | 0.880 |
Why?
|
Administration, Oral | 19 | 2024 | 4044 | 0.870 |
Why?
|
Thiophenes | 4 | 2014 | 587 | 0.730 |
Why?
|
Atherosclerosis | 5 | 2023 | 3524 | 0.720 |
Why?
|
Thrombolytic Therapy | 6 | 2018 | 2108 | 0.670 |
Why?
|
Lipase | 1 | 2021 | 324 | 0.660 |
Why?
|
Pyridones | 5 | 2024 | 788 | 0.660 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2023 | 3333 | 0.630 |
Why?
|
Anticholesteremic Agents | 3 | 2022 | 988 | 0.630 |
Why?
|
Venous Thromboembolism | 5 | 2024 | 1866 | 0.600 |
Why?
|
Hypoglycemic Agents | 5 | 2024 | 3149 | 0.580 |
Why?
|
Risk Factors | 48 | 2024 | 74269 | 0.570 |
Why?
|
Ischemic Attack, Transient | 1 | 2023 | 899 | 0.570 |
Why?
|
Risk Assessment | 30 | 2024 | 24086 | 0.570 |
Why?
|
Coronary Artery Disease | 6 | 2023 | 6661 | 0.560 |
Why?
|
Aged | 91 | 2024 | 168995 | 0.550 |
Why?
|
Anti-Arrhythmia Agents | 3 | 2017 | 784 | 0.540 |
Why?
|
Natriuretic Peptide, Brain | 6 | 2024 | 1705 | 0.510 |
Why?
|
Treatment Outcome | 52 | 2024 | 64947 | 0.510 |
Why?
|
Purinergic P2Y Receptor Antagonists | 3 | 2015 | 379 | 0.490 |
Why?
|
Humans | 152 | 2024 | 760261 | 0.480 |
Why?
|
Pyrazoles | 5 | 2024 | 1992 | 0.460 |
Why?
|
Brain Ischemia | 4 | 2023 | 3127 | 0.460 |
Why?
|
Antibodies, Antiphospholipid | 1 | 2014 | 71 | 0.460 |
Why?
|
Ticlopidine | 4 | 2014 | 895 | 0.450 |
Why?
|
Phosphorylcholine | 1 | 2014 | 153 | 0.440 |
Why?
|
Hemostatics | 1 | 2016 | 243 | 0.440 |
Why?
|
Amiodarone | 1 | 2015 | 218 | 0.440 |
Why?
|
Antithrombins | 1 | 2016 | 313 | 0.440 |
Why?
|
Middle Aged | 74 | 2024 | 220175 | 0.430 |
Why?
|
Dose-Response Relationship, Drug | 17 | 2024 | 10829 | 0.430 |
Why?
|
Kidney Diseases | 2 | 2021 | 2093 | 0.420 |
Why?
|
Benzazepines | 3 | 2019 | 311 | 0.410 |
Why?
|
Heart Failure | 14 | 2024 | 11835 | 0.400 |
Why?
|
Fatty Acid-Binding Proteins | 1 | 2013 | 296 | 0.390 |
Why?
|
Drug Substitution | 1 | 2014 | 296 | 0.390 |
Why?
|
Female | 92 | 2024 | 391011 | 0.390 |
Why?
|
Peptide Fragments | 5 | 2024 | 5120 | 0.380 |
Why?
|
Male | 88 | 2024 | 359413 | 0.380 |
Why?
|
Blood Coagulation | 7 | 2021 | 1156 | 0.370 |
Why?
|
Peripheral Arterial Disease | 1 | 2022 | 1305 | 0.370 |
Why?
|
Morpholines | 1 | 2014 | 583 | 0.370 |
Why?
|
Thrombosis | 4 | 2024 | 3052 | 0.360 |
Why?
|
Platelet Aggregation Inhibitors | 6 | 2022 | 3201 | 0.360 |
Why?
|
Angina, Unstable | 4 | 2013 | 926 | 0.360 |
Why?
|
Chest Pain | 3 | 2014 | 1106 | 0.360 |
Why?
|
Diabetes Mellitus, Type 2 | 8 | 2024 | 12281 | 0.350 |
Why?
|
Kidney | 3 | 2021 | 7072 | 0.350 |
Why?
|
Diabetes Mellitus | 4 | 2022 | 5884 | 0.350 |
Why?
|
Glucosides | 3 | 2019 | 536 | 0.340 |
Why?
|
Randomized Controlled Trials as Topic | 13 | 2024 | 10340 | 0.340 |
Why?
|
Cholesterol, LDL | 5 | 2022 | 2422 | 0.320 |
Why?
|
Immunoglobulin M | 1 | 2014 | 1529 | 0.320 |
Why?
|
Piperazines | 4 | 2016 | 2520 | 0.320 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 2 | 2024 | 334 | 0.320 |
Why?
|
Venous Thrombosis | 3 | 2024 | 1293 | 0.310 |
Why?
|
Accidental Falls | 1 | 2016 | 1054 | 0.310 |
Why?
|
Fibrinolytic Agents | 6 | 2019 | 2167 | 0.310 |
Why?
|
Appetite Depressants | 2 | 2019 | 108 | 0.310 |
Why?
|
Aged, 80 and over | 26 | 2024 | 58947 | 0.300 |
Why?
|
Benzhydryl Compounds | 3 | 2019 | 942 | 0.300 |
Why?
|
Lipoprotein(a) | 2 | 2024 | 499 | 0.280 |
Why?
|
Genome-Wide Association Study | 4 | 2022 | 12602 | 0.270 |
Why?
|
Troponin I | 4 | 2014 | 634 | 0.260 |
Why?
|
Growth Differentiation Factor 15 | 2 | 2024 | 192 | 0.260 |
Why?
|
Intracranial Hemorrhages | 3 | 2021 | 844 | 0.260 |
Why?
|
Atrial Function, Left | 2 | 2019 | 186 | 0.260 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 2 | 2020 | 253 | 0.250 |
Why?
|
Enoxaparin | 1 | 2007 | 397 | 0.250 |
Why?
|
Follow-Up Studies | 15 | 2021 | 39254 | 0.240 |
Why?
|
Stroke Volume | 7 | 2023 | 5513 | 0.240 |
Why?
|
Vitamin K | 3 | 2024 | 321 | 0.230 |
Why?
|
Proportional Hazards Models | 9 | 2021 | 12532 | 0.220 |
Why?
|
Pharmacogenetics | 5 | 2020 | 680 | 0.220 |
Why?
|
Osteoarthritis | 1 | 2011 | 1055 | 0.220 |
Why?
|
Virus Latency | 2 | 2002 | 362 | 0.210 |
Why?
|
Telemedicine | 1 | 2020 | 3005 | 0.210 |
Why?
|
Infusions, Subcutaneous | 1 | 2021 | 43 | 0.200 |
Why?
|
Gastric Inhibitory Polypeptide | 1 | 2022 | 66 | 0.200 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 2282 | 0.190 |
Why?
|
Troponin T | 2 | 2024 | 774 | 0.180 |
Why?
|
Endophenotypes | 1 | 2022 | 255 | 0.180 |
Why?
|
Prognosis | 10 | 2023 | 29636 | 0.180 |
Why?
|
Electronics | 1 | 2021 | 317 | 0.180 |
Why?
|
C-Reactive Protein | 2 | 2011 | 3822 | 0.170 |
Why?
|
Retrospective Studies | 11 | 2022 | 80301 | 0.170 |
Why?
|
Time Factors | 14 | 2024 | 40133 | 0.170 |
Why?
|
Cardiac Resynchronization Therapy Devices | 2 | 2019 | 122 | 0.170 |
Why?
|
International Normalized Ratio | 5 | 2020 | 387 | 0.160 |
Why?
|
Serotonin 5-HT2 Receptor Agonists | 1 | 2019 | 31 | 0.160 |
Why?
|
Off-Label Use | 1 | 2021 | 184 | 0.160 |
Why?
|
Critical Pathways | 1 | 2022 | 475 | 0.160 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2020 | 179 | 0.160 |
Why?
|
Appetite Regulation | 1 | 2019 | 84 | 0.160 |
Why?
|
Inappropriate Prescribing | 1 | 2021 | 209 | 0.150 |
Why?
|
Cause of Death | 6 | 2019 | 3723 | 0.150 |
Why?
|
Long QT Syndrome | 1 | 2022 | 465 | 0.150 |
Why?
|
Incidence | 8 | 2021 | 21378 | 0.150 |
Why?
|
Biomedical Technology | 1 | 2020 | 211 | 0.150 |
Why?
|
Ventricular Function, Left | 3 | 2019 | 3870 | 0.150 |
Why?
|
Prospective Studies | 12 | 2022 | 54263 | 0.140 |
Why?
|
Placebos | 1 | 2021 | 1672 | 0.140 |
Why?
|
Death, Sudden, Cardiac | 3 | 2016 | 1572 | 0.140 |
Why?
|
Echocardiography | 3 | 2019 | 4980 | 0.140 |
Why?
|
Obesity | 4 | 2019 | 12915 | 0.130 |
Why?
|
Digoxin | 1 | 2017 | 247 | 0.130 |
Why?
|
Electrocardiography | 3 | 2018 | 6413 | 0.130 |
Why?
|
Factor VIIa | 1 | 2016 | 103 | 0.130 |
Why?
|
Hospitalization | 6 | 2022 | 10761 | 0.130 |
Why?
|
Heart Atria | 2 | 2019 | 1344 | 0.130 |
Why?
|
Genotype | 6 | 2022 | 12959 | 0.130 |
Why?
|
Placebo Effect | 1 | 2019 | 511 | 0.130 |
Why?
|
Arthritis, Rheumatoid | 1 | 2011 | 3763 | 0.130 |
Why?
|
Electric Countershock | 1 | 2018 | 537 | 0.120 |
Why?
|
Primary Prevention | 1 | 2023 | 1207 | 0.120 |
Why?
|
Cholesterol, HDL | 1 | 2021 | 1817 | 0.120 |
Why?
|
Anti-Obesity Agents | 1 | 2018 | 229 | 0.120 |
Why?
|
Drug Utilization | 1 | 2021 | 1195 | 0.120 |
Why?
|
Drug Discovery | 1 | 2022 | 1056 | 0.120 |
Why?
|
Catheter Ablation | 2 | 2018 | 2755 | 0.120 |
Why?
|
Prosthesis Implantation | 1 | 2019 | 593 | 0.120 |
Why?
|
Longitudinal Studies | 3 | 2024 | 14482 | 0.120 |
Why?
|
Blood Coagulation Factors | 1 | 2016 | 366 | 0.110 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2002 | 1894 | 0.110 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2018 | 1130 | 0.110 |
Why?
|
Device Removal | 1 | 2019 | 634 | 0.110 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2002 | 4355 | 0.110 |
Why?
|
Withholding Treatment | 1 | 2018 | 613 | 0.110 |
Why?
|
Overweight | 3 | 2019 | 2421 | 0.110 |
Why?
|
Pacemaker, Artificial | 1 | 2019 | 815 | 0.110 |
Why?
|
Plasma | 1 | 2016 | 584 | 0.110 |
Why?
|
Weight Loss | 3 | 2019 | 2683 | 0.110 |
Why?
|
Single-Blind Method | 1 | 2016 | 1577 | 0.100 |
Why?
|
Arginine | 1 | 2016 | 934 | 0.100 |
Why?
|
Cardiovascular Agents | 1 | 2019 | 864 | 0.100 |
Why?
|
Glycopeptides | 1 | 2014 | 220 | 0.100 |
Why?
|
Bioprosthesis | 1 | 2017 | 599 | 0.100 |
Why?
|
Dyslipidemias | 1 | 2020 | 895 | 0.100 |
Why?
|
Electrodes, Implanted | 1 | 2017 | 833 | 0.100 |
Why?
|
Defibrillators, Implantable | 2 | 2019 | 1499 | 0.100 |
Why?
|
Calgranulin A | 1 | 2012 | 80 | 0.100 |
Why?
|
Calgranulin B | 1 | 2012 | 86 | 0.100 |
Why?
|
Social Class | 1 | 2021 | 2005 | 0.100 |
Why?
|
Perioperative Care | 2 | 2018 | 1032 | 0.100 |
Why?
|
Thorax | 3 | 2019 | 553 | 0.100 |
Why?
|
Out-of-Hospital Cardiac Arrest | 1 | 2016 | 347 | 0.100 |
Why?
|
Aortic Valve Stenosis | 1 | 2024 | 2064 | 0.090 |
Why?
|
Apolipoproteins B | 2 | 2024 | 388 | 0.090 |
Why?
|
Renal Dialysis | 1 | 2021 | 1802 | 0.090 |
Why?
|
Hypoglycemia | 1 | 2018 | 888 | 0.090 |
Why?
|
Platelet Aggregation | 1 | 2014 | 805 | 0.090 |
Why?
|
Diclofenac | 1 | 2011 | 67 | 0.090 |
Why?
|
Health Status Indicators | 1 | 2016 | 968 | 0.090 |
Why?
|
HIV-1 | 3 | 2002 | 6850 | 0.090 |
Why?
|
Liver Diseases | 1 | 2019 | 1301 | 0.090 |
Why?
|
Body Weight | 4 | 2024 | 4613 | 0.090 |
Why?
|
Glomerular Filtration Rate | 1 | 2019 | 2178 | 0.090 |
Why?
|
Genetic Predisposition to Disease | 3 | 2024 | 17766 | 0.090 |
Why?
|
Cyclophosphamide | 1 | 2015 | 2220 | 0.080 |
Why?
|
Heart Valve Diseases | 1 | 2017 | 1047 | 0.080 |
Why?
|
Troponin | 1 | 2013 | 516 | 0.080 |
Why?
|
Hyperlipidemias | 1 | 2013 | 782 | 0.080 |
Why?
|
Medication Adherence | 2 | 2020 | 2163 | 0.080 |
Why?
|
Sulfones | 1 | 2011 | 447 | 0.080 |
Why?
|
Heart Valve Prosthesis | 1 | 2017 | 1494 | 0.080 |
Why?
|
Platelet Activation | 1 | 2011 | 661 | 0.080 |
Why?
|
Risk | 3 | 2019 | 9629 | 0.070 |
Why?
|
Proteomics | 1 | 2021 | 3810 | 0.070 |
Why?
|
Polymorphism, Genetic | 1 | 2018 | 4286 | 0.070 |
Why?
|
Thrombin | 1 | 2010 | 593 | 0.070 |
Why?
|
Cohort Studies | 4 | 2023 | 41317 | 0.070 |
Why?
|
Comorbidity | 5 | 2020 | 10552 | 0.070 |
Why?
|
Severity of Illness Index | 3 | 2021 | 15827 | 0.070 |
Why?
|
United States Food and Drug Administration | 1 | 2015 | 1675 | 0.070 |
Why?
|
Socioeconomic Factors | 1 | 2021 | 7803 | 0.070 |
Why?
|
Hypertension | 2 | 2019 | 8595 | 0.070 |
Why?
|
Recombinant Proteins | 1 | 2016 | 6543 | 0.070 |
Why?
|
Anti-HIV Agents | 1 | 2002 | 4492 | 0.070 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2017 | 1583 | 0.070 |
Why?
|
CD40 Ligand | 1 | 2008 | 522 | 0.070 |
Why?
|
Disease Management | 1 | 2017 | 2508 | 0.070 |
Why?
|
Metabolic Clearance Rate | 2 | 2016 | 361 | 0.070 |
Why?
|
Registries | 2 | 2013 | 8449 | 0.070 |
Why?
|
Drug Administration Schedule | 3 | 2019 | 4900 | 0.060 |
Why?
|
Adult | 8 | 2023 | 219847 | 0.060 |
Why?
|
Alzheimer Disease | 3 | 2022 | 8551 | 0.060 |
Why?
|
Prevalence | 2 | 2013 | 15687 | 0.060 |
Why?
|
Factor XIa | 1 | 2024 | 9 | 0.060 |
Why?
|
Databases, Factual | 1 | 2020 | 8018 | 0.060 |
Why?
|
Peroxidase | 1 | 2008 | 604 | 0.060 |
Why?
|
Virus Replication | 2 | 2002 | 2431 | 0.060 |
Why?
|
Health Status | 1 | 2017 | 4081 | 0.060 |
Why?
|
ROC Curve | 3 | 2019 | 3568 | 0.060 |
Why?
|
Genes, pol | 1 | 2002 | 52 | 0.050 |
Why?
|
Cardiac Surgical Procedures | 1 | 2018 | 3618 | 0.050 |
Why?
|
HIV Protease | 1 | 2002 | 97 | 0.050 |
Why?
|
Atrial Flutter | 1 | 2024 | 258 | 0.050 |
Why?
|
Dipeptidyl Peptidase 4 | 1 | 2022 | 91 | 0.050 |
Why?
|
Multicenter Studies as Topic | 2 | 2020 | 1723 | 0.050 |
Why?
|
DNA, Circular | 1 | 2002 | 97 | 0.050 |
Why?
|
HIV Infections | 3 | 2002 | 17159 | 0.050 |
Why?
|
HIV Reverse Transcriptase | 1 | 2002 | 212 | 0.050 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 2009 | 1880 | 0.050 |
Why?
|
Recurrence | 4 | 2019 | 8487 | 0.050 |
Why?
|
Blood Platelets | 1 | 2011 | 2522 | 0.050 |
Why?
|
Emergency Medical Services | 1 | 2012 | 1927 | 0.050 |
Why?
|
Drug Monitoring | 2 | 2018 | 966 | 0.050 |
Why?
|
Subtilisins | 1 | 2020 | 82 | 0.050 |
Why?
|
Virus Integration | 1 | 2002 | 302 | 0.040 |
Why?
|
Africa | 1 | 2022 | 707 | 0.040 |
Why?
|
Heparin | 1 | 2007 | 1655 | 0.040 |
Why?
|
Population Surveillance | 1 | 2010 | 2609 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2019 | 15766 | 0.040 |
Why?
|
United States | 7 | 2019 | 72363 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 6545 | 0.040 |
Why?
|
Virulence | 1 | 2022 | 1295 | 0.040 |
Why?
|
Computer Security | 1 | 2020 | 260 | 0.040 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 489 | 0.040 |
Why?
|
Biomarkers, Pharmacological | 1 | 2019 | 162 | 0.040 |
Why?
|
Creatine Kinase, MB Form | 2 | 2009 | 211 | 0.040 |
Why?
|
Young Adult | 2 | 2023 | 58673 | 0.040 |
Why?
|
Disease Progression | 3 | 2019 | 13505 | 0.040 |
Why?
|
Arrhythmias, Cardiac | 1 | 2007 | 2255 | 0.040 |
Why?
|
Septal Occluder Device | 1 | 2018 | 126 | 0.040 |
Why?
|
Half-Life | 1 | 2018 | 652 | 0.040 |
Why?
|
Apolipoprotein E4 | 1 | 2022 | 708 | 0.040 |
Why?
|
Aspirin | 2 | 2020 | 3365 | 0.040 |
Why?
|
Medication Therapy Management | 1 | 2018 | 132 | 0.040 |
Why?
|
Drug Resistance, Viral | 1 | 2002 | 859 | 0.040 |
Why?
|
Latin America | 1 | 2018 | 405 | 0.040 |
Why?
|
Neurofibrillary Tangles | 1 | 1999 | 457 | 0.040 |
Why?
|
Lipoproteins | 1 | 2022 | 882 | 0.040 |
Why?
|
Clinical Trials as Topic | 3 | 2020 | 8058 | 0.030 |
Why?
|
Plasmids | 1 | 2002 | 2277 | 0.030 |
Why?
|
Digitalis Glycosides | 1 | 2016 | 47 | 0.030 |
Why?
|
Health Services Misuse | 1 | 2018 | 245 | 0.030 |
Why?
|
Germany | 1 | 2019 | 875 | 0.030 |
Why?
|
Biological Availability | 1 | 2016 | 395 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2018 | 15680 | 0.030 |
Why?
|
Europe | 1 | 2022 | 3433 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2022 | 1791 | 0.030 |
Why?
|
Diet, Reducing | 1 | 2019 | 487 | 0.030 |
Why?
|
Lymphocytes | 1 | 2023 | 2612 | 0.030 |
Why?
|
Phylogeny | 1 | 2002 | 2775 | 0.030 |
Why?
|
Survival Analysis | 2 | 2019 | 10185 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2018 | 859 | 0.030 |
Why?
|
Multifactorial Inheritance | 1 | 2022 | 1351 | 0.030 |
Why?
|
Benzamides | 1 | 2020 | 1369 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2016 | 680 | 0.030 |
Why?
|
Aortic Valve Insufficiency | 1 | 2018 | 584 | 0.030 |
Why?
|
Body Mass Index | 2 | 2024 | 12901 | 0.030 |
Why?
|
Safety | 1 | 2018 | 1149 | 0.030 |
Why?
|
Sensitivity and Specificity | 3 | 2014 | 14656 | 0.030 |
Why?
|
Survival Rate | 2 | 2019 | 12806 | 0.030 |
Why?
|
Thrombophilia | 1 | 2016 | 307 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2019 | 2061 | 0.030 |
Why?
|
Cardiotonic Agents | 1 | 2016 | 546 | 0.030 |
Why?
|
Amyloid beta-Protein Precursor | 1 | 1998 | 1110 | 0.030 |
Why?
|
Molecular Sequence Data | 2 | 2002 | 17628 | 0.030 |
Why?
|
Remission Induction | 1 | 2018 | 2394 | 0.030 |
Why?
|
Cholesterol | 1 | 2022 | 2925 | 0.030 |
Why?
|
Prediabetic State | 1 | 2018 | 550 | 0.030 |
Why?
|
Age Factors | 2 | 2022 | 18415 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2019 | 1109 | 0.030 |
Why?
|
Information Dissemination | 1 | 2020 | 1132 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2002 | 4717 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2022 | 2805 | 0.020 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2016 | 853 | 0.020 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2018 | 951 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2002 | 13456 | 0.020 |
Why?
|
Pandemics | 1 | 2010 | 8621 | 0.020 |
Why?
|
Creatinine | 1 | 2016 | 1906 | 0.020 |
Why?
|
Internationality | 1 | 2016 | 1005 | 0.020 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2016 | 1256 | 0.020 |
Why?
|
Neutrophils | 1 | 2023 | 3770 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2753 | 0.020 |
Why?
|
Causality | 1 | 2016 | 1241 | 0.020 |
Why?
|
Platelet Function Tests | 1 | 2011 | 303 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2016 | 1548 | 0.020 |
Why?
|
Infant | 2 | 2021 | 36030 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2017 | 2325 | 0.020 |
Why?
|
Critical Illness | 1 | 2022 | 2709 | 0.020 |
Why?
|
Neoplasms | 1 | 2018 | 22066 | 0.020 |
Why?
|
Neuropsychological Tests | 1 | 2022 | 7016 | 0.020 |
Why?
|
Drug Approval | 1 | 2015 | 816 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2018 | 2311 | 0.020 |
Why?
|
Sex Factors | 1 | 2022 | 10530 | 0.020 |
Why?
|
Hypertension, Pulmonary | 1 | 2018 | 1570 | 0.020 |
Why?
|
Mortality | 1 | 2018 | 2916 | 0.020 |
Why?
|
Patient Discharge | 1 | 2020 | 3475 | 0.020 |
Why?
|
American Heart Association | 1 | 2011 | 1081 | 0.020 |
Why?
|
Homozygote | 1 | 2011 | 1786 | 0.020 |
Why?
|
Pulmonary Embolism | 1 | 2020 | 2544 | 0.020 |
Why?
|
Coronary Angiography | 1 | 2018 | 4560 | 0.020 |
Why?
|
Ventricular Remodeling | 1 | 2013 | 1259 | 0.020 |
Why?
|
Nerve Tissue Proteins | 1 | 1998 | 4409 | 0.020 |
Why?
|
Genomics | 1 | 2021 | 5790 | 0.020 |
Why?
|
DNA, Viral | 2 | 2002 | 2195 | 0.020 |
Why?
|
International Cooperation | 1 | 2011 | 1436 | 0.020 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2008 | 638 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2014 | 15273 | 0.020 |
Why?
|
Heterozygote | 1 | 2011 | 2797 | 0.020 |
Why?
|
Heart Rate | 1 | 2016 | 4169 | 0.010 |
Why?
|
Logistic Models | 1 | 2019 | 13311 | 0.010 |
Why?
|
Cognition | 1 | 2022 | 6948 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2016 | 3561 | 0.010 |
Why?
|
Computer Simulation | 1 | 2017 | 6210 | 0.010 |
Why?
|
Pilot Projects | 1 | 2017 | 8553 | 0.010 |
Why?
|
Patient Selection | 1 | 2015 | 4276 | 0.010 |
Why?
|
Acute Disease | 1 | 2014 | 7268 | 0.010 |
Why?
|
Blood Pressure | 1 | 2019 | 8523 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12156 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7468 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 5507 | 0.010 |
Why?
|
HIV Long Terminal Repeat | 1 | 2002 | 85 | 0.010 |
Why?
|
HIV Integrase | 1 | 2002 | 121 | 0.010 |
Why?
|
Massachusetts | 1 | 2014 | 8805 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2018 | 22041 | 0.010 |
Why?
|
Models, Biological | 1 | 2016 | 9468 | 0.010 |
Why?
|
Genetic Variation | 1 | 2015 | 6540 | 0.010 |
Why?
|
Child, Preschool | 1 | 2002 | 42034 | 0.010 |
Why?
|
Aging | 1 | 1998 | 8641 | 0.010 |
Why?
|
Algorithms | 1 | 2020 | 13967 | 0.010 |
Why?
|
Spectrometry, Fluorescence | 1 | 1999 | 686 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2009 | 8551 | 0.010 |
Why?
|
Quality of Life | 1 | 2017 | 13300 | 0.010 |
Why?
|
Tissue Distribution | 1 | 1999 | 2262 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2018 | 11341 | 0.010 |
Why?
|
Plaque, Amyloid | 1 | 1999 | 758 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 1998 | 1900 | 0.010 |
Why?
|
Cadaver | 1 | 1998 | 1345 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2014 | 7809 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2018 | 13249 | 0.010 |
Why?
|
Enzyme Activation | 1 | 1999 | 3604 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2002 | 6067 | 0.010 |
Why?
|
Base Sequence | 1 | 2002 | 12447 | 0.010 |
Why?
|
tau Proteins | 1 | 1999 | 2095 | 0.000 |
Why?
|
Transcription, Genetic | 1 | 2002 | 7593 | 0.000 |
Why?
|
Phosphorylation | 1 | 1999 | 8314 | 0.000 |
Why?
|
Immunohistochemistry | 1 | 1998 | 11064 | 0.000 |
Why?
|
Brain | 1 | 1999 | 26912 | 0.000 |
Why?
|